2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
12
Neoplasms
8
Carcinoid Tumor
7
Diarrhea
6
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
6
Breast Neoplasms
5
Acromegaly
5
Vipoma
4
Stomach Neoplasms
4
Somatostatinoma
4
Rectal Neoplasms
4
Insulinoma
4
Glucagonoma
4
Gastro-enteropancreatic neuroendocrine tumor
4
Esophageal Neoplasms
4
Carcinoma, Islet Cell
4
Adenoma, Islet Cell
4
Weight Loss
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Intestinal Obstruction
3
Gastrinoma
3
Colonic Neoplasms
3
Carcinoma
3
Thymoma
2
Pituitary Neoplasms
2
Ovarian Neoplasms
2
Meningioma
2
Interventions
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Malignant Carcinoid Syndrome
×
Octreotide
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts